Sign in
SGEN Stock Price, Chart, Stats & News
Seagen Inc.
Save
43.15B
Market cap
–
Current P/E
–
Forward P/E
SGEN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 79.10% |
Operating margin | -31.24% |
Pretax margin | -30.69% |
Net margin | -31.10% |
Effective tax rate | -1.33% |
ROA | -16.61% |
ROE | -20.80% |
D/E | 0.02x |
Interest coverage ratio | – |
SGEN valuation
P/E | – |
P/S | 21.99x |
P/B | 15.07x |
P/CF | -93.10x |
P/FCF | -81.26x |
P/OCF | -93.10x |
PEG | -0.69x |
EV multiple | -69.64x |
About
Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies.
Similar securities
Based on sector and market capitalization
Report issue